Archive
Proactive news snapshot: Gaming Realms, Sareum Holdings, Anglo Asian Mining …
A glance at some of the day's highlights from the Proactive Investors newswire
Company
Sareum Holdings PLC
LON:SAR
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer. The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, including psoriasis, and has completed Phase 1 clinical development.
239 stories · page 4 of 12
Sareum Holdings created drug to be showcased at leading cancer event next month
Sareum's partner Sierra Oncology has provided the essence of what it will share with delegates at the upcoming American Society of Clinical Oncology in Chicago
Archive
Proactive news snapshot: Sirius Minerals, AFC Energy, Location Sciences …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Solid State sparks rally with bullish trading update
A look at some of the biggest risers and fallers in London on Tuesday
Investments and investor services
Air Partners appoints MD of its charter division
A look at the day's major movers, including Quadrise, Intu Properties, Mediazest, Upland Resources, MX Oil and Angling Direct
Archive
Proactive news snapshot: Active Energy, Tekcapital, Sareum Holdings …
A glance at some of the day's highlights from the Proactive Investors newswire
Sareum Holdings jumps as it says new data on cancer drug to be released at top conference
The update is being presented in the form of two abstracts at the American Society of Clinical Oncology in Chicago
Investments and investor services
FTSE 100 closes at near seven month high as no news is deemed good news
The UK blue-chip index finished up around 63 points at 7,523
Sareum’s flagship Chk1 inhibitor shows serious lung cancer potential in mouse models
After 50 days, eight out of ten mice achieved a complete response, which means there was no detectable sign of cancer anymore
Archive
Proactive news snapshot: Tekcapital, Mirada, European Metals Holdings …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Superdry investors in danger of losing their shirt after Dunkerton prevails in power struggle
A look at the day's major movers, including Clear Leisure, Proteome, Intercede, MP Evans, Zenith Energy, Infrastructure India and Sabien Technology
Investments and investor services
GAN trumpets winning of an industry award ... the shares fall
A look at the day's major movers, including Gulf Marine Services, Boxhill, Chesterfield Resources, Proton Power, Abcam, Tandem, Red Emperor and FFI
Archive
Proactive news snapshot: Shield Therapeutics, Plexus Holdings, 88 Energy …
A glance at some of the day's highlights from the Proactive Investors newswire
Sareum boss “very pleased” with progress of flagship Chk1 inhibitor
US firm Sierra Oncology has licensed the molecule and the results from two early-stage ovarian cancer studies are due in the current half
Investments and investor services
FTSE 100 finishes ahead on US-China optimism; Rightmove top gainer
The UK blue-chip benchmark finished around 27 points higher at 7,134